Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Prostate Cancer and Prostatic Diseases
(ISSN: 1365-7852, 1476-5608)
This journal no longer participates in Medscape Publishers' Circle Program. No new articles will be republished.
Erectile dysfunction is a common side effect of radical prostatectomy in prostate cancer patients -- but certain non-surgically related aspects may also impact erectile function recovery.
A new study provides insight into the health-related quality of life impacts of new treatment options for metastatic castration-resistant prostate cancer -- from the patient's perspective.
Prostate biopsy and fiducial placement in the same sitting- a good option during COVID pandemic as well as in patients on anticoagulants/antiplatelets.
Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: a prospective randomized clinical trial.
Psychological distress in men with prostate cancer undertaking androgen deprivation therapy: modifying effects of exercise from a year-long randomized controlled trial.
Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre.
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer?
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England.
Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
